{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg", "query": { "intervention": "Placebo 50 or 100 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 281, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+50+or+100+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T13:26:47.742Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01856309", "title": "Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "Sirukumab 100 mg", "type": "DRUG" }, { "name": "Sirukumab 50 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1820, "start_date": "2013-08-07", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2019-05-06", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 63 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01856309" }, { "nct_id": "NCT04129931", "title": "PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "MCT", "type": "DRUG" }, { "name": "Clazakizumab", "type": "DRUG" }, { "name": "Broncho-Vaxom", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" }, { "name": "Cavosonstat", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 950, "start_date": "2019-12-19", "completion_date": "2025-03-19", "has_results": true, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 29, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04129931" }, { "nct_id": "NCT02654002", "title": "Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonalcoholic Steatohepatitis (NASH)" ], "interventions": [ { "name": "Cilofexor", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 120, "start_date": "2016-01-20", "completion_date": "2016-07-14", "has_results": true, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02654002" }, { "nct_id": "NCT00298272", "title": "Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "IDEC-C2B8 (rituximab)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Folate", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 54, "start_date": "2006-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298272" }, { "nct_id": "NCT00326339", "title": "Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "R788", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rigel Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 189, "start_date": "2006-08", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2009-04-20", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 27, "location_summary": "Santa Maria, California • Ocala, Florida • Orange Park, Florida + 22 more", "locations": [ { "city": "Santa Maria", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orange Park", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00326339" }, { "nct_id": "NCT00600119", "title": "A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Opioid Induced Constipation (OIC)" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "NKTR-118", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2007-12", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2015-06-12", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 33, "location_summary": "Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pinson", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00600119" }, { "nct_id": "NCT02717988", "title": "Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SKI-O-703 capsule", "type": "DRUG" }, { "name": "Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oscotec Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2015-09", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02717988" }, { "nct_id": "NCT01087736", "title": "Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "PTSD", "Alcohol Abuse", "Alcoholism" ], "interventions": [ { "name": "Topiramate", "type": "DRUG" }, { "name": "Placebo administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2010-04", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-06-03", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087736" }, { "nct_id": "NCT00906269", "title": "Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Impotence", "Prostatic Neoplasms" ], "interventions": [ { "name": "Sildenafil therapy plus post-NSRRP HBO2T", "type": "DRUG" }, { "name": "Sildenafil therapy plus sham post-NSRRP HBO2T", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hartford Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "40 Years to 65 Years · Male only" }, "enrollment_count": 100, "start_date": "2009-07", "completion_date": "2021-01", "has_results": false, "last_update_posted_date": "2019-05-20", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 1, "location_summary": "Hartford, Connecticut", "locations": [ { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00906269" }, { "nct_id": "NCT00249912", "title": "Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Lapaquistat acetate and rosuvastatin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 415, "start_date": "2005-10", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2012-05-24", "last_synced_at": "2026-10-02T13:26:47.742Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Haleyville, Alabama • Mobile, Alabama + 79 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Haleyville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249912" } ] }